Answers are grounded in this paper and cite their sources.
Innovative biomarkers as well as new modalities to integrate structural information at higher level should be tuned up in order to understand the mechanisms underlying the pathology evolution. Here, we show some results obtained by integrating morphological information from X-ray phase contrast microtomography with histology combined with immunohistochemistry. Thanks to this approach, we demonstrated the possibility to use the cell number variation as a biomarker for pathological conditions.
No takes yet. Share an insight, caveat, or question.
Maugeri et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: